[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361078-105":59,"doc-detail-361078-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","checkpoint-inhibitor-pneumonitis-in-lung-cancer-patients-receiving-immune-checkpoint-inhibitors-prior-to-chest-radiotherapy-research-open-access","Checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors prior to chest radiotherapy - Research Open Access","","Immune checkpoint inhibitors have become a standard treatment for lung cancer, improving survival but increasing adverse events that may affect patient safety and subsequent therapy. This study evaluates checkpoint inhibitor pneumonitis in lung cancer patients who received ICIs before chest radiotherapy. From October 2018 to September 2024, 52 patients were followed for clinical characteristics, CIP incidence, prognosis, and hypersensitive C-reactive protein levels. The findings show a relatively high CIP incidence and suggest hsCRP monitoring for early detection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/checkpoint-inhibitor-pneumonitis-in-lung-cancer-patients-receiving-immune-checkpoint-inhibitors-prior-to-chest-radiotherapy-research-open-access/361078/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/checkpoint-inhibitor-pneumonitis-in-lung-cancer-patients-receiving-immune-checkpoint-inhibitors-prior-to-chest-radiotherapy-research-open-access/361078.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective?","Question",{"text":112,"@type":113},"To assess checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors before chest radiotherapy, including related clinical factors and hsCRP levels.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients developed checkpoint inhibitor pneumonitis after prior ICI exposure?",{"text":117,"@type":113},"Among 52 patients treated with ICIs before chest-RT, 21.2% (11/52) developed checkpoint inhibitor pneumonitis.",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarker did the study highlight for early detection?",{"text":121,"@type":113},"hsCRP, described as a simple and cost-effective biomarker, may help clinicians detect CIP early and intervene promptly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361078,1790727623,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Fu etal. BMC Cancer (2026) 26:920 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16267-w](https://doi.org/10.1186/s12885-026-16267-w)  \nRESEARCH Open Access  \nCheckpoint inhibitor pneumonitis in lung  cancer patients receiving immune checkpoint inhibitors prior to chest radiotherapy  \nYue-Chun Fu 1†, Si-Dong Xie2†, Xian-Yu Guo3†, Zheng-Huan Li3, Bing Pang3, Dong-Hui Wang3, Xiang-Ying Xu3* and Shao-Bo Liang3*  \nAbstract  \nBackground Immune checkpoint inhibitors (ICIs) have become a standard treatment method for lung cancer in recent years. While they improve survival, they are associated with adverse effects affecting the safety of patients and their subsequent treatment. This study aimed to assess checkpoint inhibitor pneumonitis (CIP) in lung cancer patients receiving ICIs prior to chest radiotherapy (chest-RT) .  \nMaterials and methods Between October 2018 and September 2024, 52 lung cancer patients who received ICIs before chest-RT were enrolled in the hospital. Clinical characteristics, treatment details, incidence of CIP, prognosis, and hypersensitive C-reactive protein (hsCRP) levels were collected. Associations between clinical characteristics, treatment, hsCRP, and CIP were analyzed.  \nResults Among patients treated with ICIs before chest-RT, 21 . 2%(11/52) developed CIP. Compared with patients without CIP, those with CIP had higher proportions ofT4 stage (54 . 5% vs. 31. 7%), N3 stage (45 . 5% vs. 26. 8%), and stage IIIc-IV disease (45 . 5% vs. 22. 0%) although these differences are not statistically significant. The impact of treatment on CIP was significant for the percent volume of lung receiving ≥ 20 Gy (V20, \u003C 28% vs. ≥ 28%), P = 0.042. Among 11 patients with CIP, two patients died from CIP and three were unable to complete radiotherapy due to toxicity. The mean value of the highest hsCRP in patients with CIP were 79.3 mg/L (25 .6-195.5 mg/L), and pretreatment mean values of hsCRP for these patients were 5.7 mg/L (0 .5–11.9 mg/L), compared to the hightest hsCRP 23.8 mg/L (0 .9- 190.3 mg/L) in patients without CIP.  \nConclusions Lung cancer patients receiving ICIs prior to chest-RT have a relatively high incidence of CIP, particularly those with high V20 . Monitoring hsCRP, a simple and cost-effective biomarker, may allow clinicians to detect CIP early and intervene promptly.  \n†Yue-Chun Fu, Si-Dong Xie and Xian-Yu Guo contributed equally to this work.  \n*Correspondence:  \nXiang-Ying Xu [Lifz1977@163.com](Lifz1977@163.com)  \nShao-Bo Liang [liangshb3@mail.sysu.edu.cn](liangshb3@mail.sysu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nFu et al. BMC Cancer (2026) 26:920 Page 2 of 9  \nKeywords Lung cancer, Immune checkpoint inhibitors, Chest radiotherapy, Checkpoint inhibitor pneumonitis, Hypersensitive C-reactive protein  \nIntroduction  \nData from the Inte","cbCaiudZ7t2zIPEc","https://ap.wps.com/l/cbCaiudZ7t2zIPEc","pdf",1396674,"English","# Abstract\n# Introduction\n# Materials and methods\n# Results\n# Conclusions","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To assess checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors before chest radiotherapy, including related clinical factors and hsCRP levels.\"},{\"question\":\"How many patients developed checkpoint inhibitor pneumonitis after prior ICI exposure?\",\"answer\":\"Among 52 patients treated with ICIs before chest-RT, 21.2% (11/52) developed checkpoint inhibitor pneumonitis.\"},{\"question\":\"What biomarker did the study highlight for early detection?\",\"answer\":\"hsCRP, described as a simple and cost-effective biomarker, may help clinicians detect CIP early and intervene promptly.\"}]","Checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors prior to chest radiotherapy - Research Open Access | PDF",1790143049,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e7fdae418770d235f5f3f9158838789.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50df2d962ddf566eb58e9b8de4d3dbc2.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6dd3bf57f972d2d579eaa61e0e45f28.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4af1c38671fb9e561e5a7a7cfe8e644.webp",980,1306]